Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

BACKGROUND: Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk of cardiovascular disease mortality. This Phase IIb safety study (AleNephro) in patients with stage 3 chronic kidney disease and type 2 diabetes, evaluated the renal effects of alegl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruilope, Luis, Hanefeld, Markolf, Lincoff, A Michael, Viberti, Giancarlo, Meyer-Reigner, Sylvie, Mudie, Nadejda, Wieczorek Kirk, Dominika, Malmberg, Klas, Herz, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364102/
https://www.ncbi.nlm.nih.gov/pubmed/25407798
http://dx.doi.org/10.1186/1471-2369-15-180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364102/
https://www.ncbi.nlm.nih.gov/pubmed/25407798
http://dx.doi.org/10.1186/1471-2369-15-180

Ejemplares similares